Malaria remains the most deadly parasitic disease in the world. Although it is not endemic to countries such as Spain, imported cases are diagnosed each year in people returning from areas where the ...

FILE PHOTO: Test tubes are seen in front of a displayed Biontech logo in this illustration BERLIN (Reuters) -BioNTech on Friday initiated an early-stage study to evaluate its experimental malaria ...

A multicentre study conducted by researchers from West Africa and the UK evaluated a portable molecular malaria test that can detect asymptomatic and submicroscopic infections in under 45 minutes, ...

A novel testing platform under development by researchers at the Yale School of Public Health (YSPH) and CytoAstra, LLC could provide a new noninvasive test for malaria that doesn't require a blood ...

Almost half of the world's population is at risk of malaria infection, with children and pregnant women at the highest risk of getting sick and dying from the disease. Current methods to detect this ...

Since 2010, a biological drama has been playing out in the bloodstreams of humans from Peru to Ethiopia. Plasmodium falciparum, the parasite that causes the most common form of malaria, has managed to ...

The cobas Malaria test will be available at the end of the second quarter of 2024. The cobas Malaria test is also intended for use in testing whole blood samples to screen organ and tissue donors when ...

The parasites that cause malaria, a disease that kills more than half a million people worldwide annually, were discovered in 1880. Almost 140 years later, there’s still no cure or vaccine for the ...

A digital polymerase chain reaction (dPCR) technique for screening malaria parasite genomes will help identify when they have mutations that allow them to dodge detection by some rapid tests, shows a ...

Scientists are trying to find a new malaria vaccine by sticking people's forearms over a box full of mosquitoes. Researchers at the University of Washington are using mosquitoes to inject human ...

BERLIN, Dec 23 (Reuters) - BioNTech (22UAy.DE), opens new tab on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said. The Phase 1 ...